ZetaChain releases ZetaClient upgrade, enabling multiple EVM calls to be executed in a single cross-chain interaction on Universal EVM
PANews reported on November 25 that ZetaChain has released a new version upgrade of ZetaClient, following the execution layer iteration after the UNISON (V36) mainnet launch. The core update introduces multi-deposit/multi-call capability for single cross-chain transactions in Universal Apps, and continues to advance the goal of approximately 2-second block times.
After the upgrade, a single cross-chain interaction can automatically split and trigger multi-step, multi-chain contract calls on Universal EVM, reducing reliance on off-chain orchestration for complex cross-chain processes. This capability enhances the capital efficiency and process experience of Universal DeFi/DEX, while also making it easier for AI agents’ natural language intents to be executed as complete cross-chain workflows.
The new version also improves inbound stability under high load, paves the way for faster keysigning and stronger observability, and expands native interoperability support for Sui (withdrawAndCall) and Solana (larger payloads).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.
Crypto prices
More
